Research ArticleCancer

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

See allHide authors and affiliations

Science Translational Medicine  17 Jan 2018:
Vol. 10, Issue 424, eaan5488
DOI: 10.1126/scitranslmed.aan5488

Doubling up against cancer

Inhibitors of immune checkpoints are increasingly used for cancer immunotherapy because they decrease cancer-associated immunosuppression and improve patients’ own immune responses against the disease. However, this type of treatment is not always sufficient to ensure protective immunity. To reinforce the effects of immune checkpoint inhibition, Lan et al. designed a bifunctional protein called M7824, which simultaneously targets an immune checkpoint and a different immunosuppressive pathway. This bifunctional protein was more effective at restoring antitumor immunity than interventions targeting one pathway at a time, and it showed promising results in multiple mouse models, alone and in combination with other treatment modalities.

View Full Text